Limits...
Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer.

Li W, Xu S, Lin S, Zhao W - J. Biomed. Biotechnol. (2012)

Bottom Line: In addition, the nuclear labeling index (LI) of RUNX2 in tumor cells was significantly associated with the advanced clinical stage of EOC tissues (P = 0.001).Especially, subgroup analysis revealed that EOC patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group, but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups.Our data suggest for the first time that RUNX2 overexpression is associated with advanced tumor progression and poor clinical outcome of EOC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynaecology and Obstetrics, Clinical Section, PLA General Hospital, Beijing 100853, China.

ABSTRACT

Aim: To investigate clinical significance of runt-related transcription factor (RUNX)-2 in epithelial ovarian cancer (EOC).

Methods: RUNX2 protein expression and its subcellular localization were detected by immunohistochemistry in 116 patients with EOC.

Results: RUNX2 protein was predominantly expressed in cell nucleus of EOC tissues. The expression level of RUNX2 in EOC tissues was significantly higher than that in normal ovarian tissues (P < 0.001). In addition, the nuclear labeling index (LI) of RUNX2 in tumor cells was significantly associated with the advanced clinical stage of EOC tissues (P = 0.001). Moreover, EOC patients with high RUNX2 LI had significantly shorter overall (P < 0.001) and progression-free (P = 0.002) survival than those with low RUNX2 LI. Especially, subgroup analysis revealed that EOC patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group, but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups.

Conclusions: Our data suggest for the first time that RUNX2 overexpression is associated with advanced tumor progression and poor clinical outcome of EOC patients. RUNX2 might be a novel prognostic marker of EOC.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier overall (a) and progression-free (b) survival curves for epithelial ovarian cancer patients with high and low RUNX2 expression. Epithelial ovarian cancer patients with high RUNX2 expression had significantly shorter overall (P < 0.001) and progression-free (P = 0.002) survival than those with low RUNX2 expression did.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3475129&req=5

fig2: Kaplan-Meier overall (a) and progression-free (b) survival curves for epithelial ovarian cancer patients with high and low RUNX2 expression. Epithelial ovarian cancer patients with high RUNX2 expression had significantly shorter overall (P < 0.001) and progression-free (P = 0.002) survival than those with low RUNX2 expression did.

Mentions: In order to investigate the prognostic implications of RUNX2 expression in overall survival and progression-free survival of EOC, the detailed clinical information of all 116 EOC patients in high RUNX2 expression and low RUNX2 expression groups was reviewed. Median follow-up time was 66.8 months (range, 2.2–118.9 months; mean, 66.1 months). At last followup, 73 (62.9%) relapsed with a median time of 22.1 months (range, 2.8–85.2 months). As determined by the log-rank test, EOC patients with high RUNX2 LI had significantly shorter overall (P < 0.001, Figure 2(a)) and progression-free (P = 0.002, Figure 2(b)) survival than those with low RUNX2 LI did. Moreover, the univariate analysis revealed that both the advanced stage (P < 0.001 and P = 0.008, resp.) and the high RUNX2 expression (P < 0.001 and P = 0.002, resp.) predicted poorer overall and progression-free survival of EOC patients (Table 2). Furthermore, the multivariate analyses identified the clinical stage (P = 0.01 and P = 0.03, resp.) and the RUNX2 LI (both P = 0.01) in EOC cells as independent prognostic factors for overall and progression-free survival (Table 3).


Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer.

Li W, Xu S, Lin S, Zhao W - J. Biomed. Biotechnol. (2012)

Kaplan-Meier overall (a) and progression-free (b) survival curves for epithelial ovarian cancer patients with high and low RUNX2 expression. Epithelial ovarian cancer patients with high RUNX2 expression had significantly shorter overall (P < 0.001) and progression-free (P = 0.002) survival than those with low RUNX2 expression did.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3475129&req=5

fig2: Kaplan-Meier overall (a) and progression-free (b) survival curves for epithelial ovarian cancer patients with high and low RUNX2 expression. Epithelial ovarian cancer patients with high RUNX2 expression had significantly shorter overall (P < 0.001) and progression-free (P = 0.002) survival than those with low RUNX2 expression did.
Mentions: In order to investigate the prognostic implications of RUNX2 expression in overall survival and progression-free survival of EOC, the detailed clinical information of all 116 EOC patients in high RUNX2 expression and low RUNX2 expression groups was reviewed. Median follow-up time was 66.8 months (range, 2.2–118.9 months; mean, 66.1 months). At last followup, 73 (62.9%) relapsed with a median time of 22.1 months (range, 2.8–85.2 months). As determined by the log-rank test, EOC patients with high RUNX2 LI had significantly shorter overall (P < 0.001, Figure 2(a)) and progression-free (P = 0.002, Figure 2(b)) survival than those with low RUNX2 LI did. Moreover, the univariate analysis revealed that both the advanced stage (P < 0.001 and P = 0.008, resp.) and the high RUNX2 expression (P < 0.001 and P = 0.002, resp.) predicted poorer overall and progression-free survival of EOC patients (Table 2). Furthermore, the multivariate analyses identified the clinical stage (P = 0.01 and P = 0.03, resp.) and the RUNX2 LI (both P = 0.01) in EOC cells as independent prognostic factors for overall and progression-free survival (Table 3).

Bottom Line: In addition, the nuclear labeling index (LI) of RUNX2 in tumor cells was significantly associated with the advanced clinical stage of EOC tissues (P = 0.001).Especially, subgroup analysis revealed that EOC patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group, but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups.Our data suggest for the first time that RUNX2 overexpression is associated with advanced tumor progression and poor clinical outcome of EOC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynaecology and Obstetrics, Clinical Section, PLA General Hospital, Beijing 100853, China.

ABSTRACT

Aim: To investigate clinical significance of runt-related transcription factor (RUNX)-2 in epithelial ovarian cancer (EOC).

Methods: RUNX2 protein expression and its subcellular localization were detected by immunohistochemistry in 116 patients with EOC.

Results: RUNX2 protein was predominantly expressed in cell nucleus of EOC tissues. The expression level of RUNX2 in EOC tissues was significantly higher than that in normal ovarian tissues (P < 0.001). In addition, the nuclear labeling index (LI) of RUNX2 in tumor cells was significantly associated with the advanced clinical stage of EOC tissues (P = 0.001). Moreover, EOC patients with high RUNX2 LI had significantly shorter overall (P < 0.001) and progression-free (P = 0.002) survival than those with low RUNX2 LI. Especially, subgroup analysis revealed that EOC patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group, but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups.

Conclusions: Our data suggest for the first time that RUNX2 overexpression is associated with advanced tumor progression and poor clinical outcome of EOC patients. RUNX2 might be a novel prognostic marker of EOC.

Show MeSH
Related in: MedlinePlus